规格：35mg 证券代码：600572 证券简称：康恩贝 公告编号：2024-068 浙江康恩贝制药股份有限公司 关于麝香通心滴丸获批国家中药保护品种 延长保护期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，国家药品监督管理局（以下简称：国家药监局）网站发布《关于中药保 护品种的公告（延长保护期第 16 号）（2024 年第 105 号）》，批准对浙江康恩贝制 药股份有限公司（以下简称：公司、本公司）全资子公司内蒙古康恩贝药业有限 公司圣龙分公司（以下简称：内蒙古康恩贝）生产的"至心砃"麝香通心滴丸继 续给予国家中药保护品种 2 级保护。现将相关情况公告如下： 一、药品基本信息 药品名称：麝香通心滴丸 剂型：丸剂 "至心砃"麝香通心滴丸为国内中药独家品种，于 2008 年获批上市，2010 年 曾经获批为国家保密品种（已到期），2017 年获批为国家中药二级保护品种，保护 期为 7 年。本次为该药品获批国家中药二级保护品种到期后的延保，保护期延长 1 功能主治：芳香益气通脉，活血化瘀止痛。用于冠心病稳定型劳累性 ...

Group 1: Company Performance Overview - In the first half of 2024, the company achieved revenue of 3.448 billion CNY, a decrease of 8.40% year-on-year [2] - The net profit attributable to shareholders was 382 million CNY, down 25.95% year-on-year [2] - The company’s revenue from major brand products accounted for 58% of total revenue, with a total income of 2 billion CNY [2][3] - The company’s revenue from online sales reached 365 million CNY, a year-on-year increase of 7.2% [13] Group 2: Strategic Adjustments and Focus Areas - The company has adjusted its business focus to promote a full range of traditional Chinese medicine (TCM) products, with TCM revenue maintaining around 50% of total revenue [5][6] - The company is enhancing its marketing capabilities across hospitals, pharmacies, and community healthcare [6] - R&D investment increased to approximately 133 million CNY in the first half of 2024, a year-on-year increase of 43.36% [14] Group 3: Product Development and Innovation - The company has made significant progress in TCM innovation, with 73% of R&D projects focused on TCM [6][9] - Key R&D projects include 6 innovative and improved new drugs, and 7 TCM secondary development projects [10] - The company aims to achieve over 100 million CNY in sales of TCM products outside Zhejiang province by 2025 [15] Group 4: Sales and Marketing Strategies - The company is enhancing brand building and expanding sales channels, including e-commerce and social media [6][8] - The sales expense ratio decreased to 31.66%, down 5.44 percentage points year-on-year, due to changes in revenue structure [20] - The company plans to optimize its product offerings in pharmacies and increase promotion efforts in clinics to adapt to changing customer flows [13] Group 5: Future Outlook and Shareholder Returns - The company has implemented a cash dividend plan, distributing 2 CNY per 10 shares for the 2023 fiscal year, totaling 3.291 billion CNY in dividends since its listing [11][12] - The company has completed its share repurchase plan, acquiring approximately 63.58 million shares for a new round of equity incentives [12]

股价表现 2024 年 08 月 27 日 康恩贝(600572.SH) 公司快报 全品类中药阶段性承压，换届完成公司 进入新时期 事件： 2024 年 8 月 23 日，公司发布 2024 年中期报告。2024 年上半年公 司实现营业收入 34.48 亿元，同比下滑 8.40%；实现归母净利润 3.82 亿元，同比下滑 25.95%；实现扣非归母净利润 3.36 亿元，同比下滑 19.02%。单季度来看，2024 年 Q2 公司实现营业收入 16.24 亿元， 同比下滑 0.60%；实现归母净利润 1.66 亿元，同比下滑 28.37%； 实现扣非归母净利润 1.35 亿元，同比下滑 11.11%。 全品类中药阶段性承压，同期高基数压力。 公司坚持以全品类中药产品为主体，以特色化学药品、特色健康消费 品为两翼的战略定位，受去年同期高基数压力，全品类中药阶段性承 压，特色化学药品和特色健康消费品表现稳健。 1）全品类中药：2024 年 H1 公司全品类中药业务实现收入 17.16 亿 元，同比下降 17.67%，其中中成药实现收入 11.31 亿元，同比下降 32.10%，主要是因为肠炎宁系列、复方鱼腥草合剂 ...

证券研究报告 非金融公司|公司点评|康恩贝（600572） 短期业绩承压，期待下半年恢复 请务必阅读报告末页的重要声明 glzqdatemark1 2024年08月26日 证券研究报告 |报告要点 公司披露 2024 年半年报，实现营收 34.48 亿元，同比下降 8.40%；归母净利润 3.82 亿元，同 比下降 25.95%；扣非归母净利润 3.36 亿元，同比下降 19.02%；单 Q2 实现营收 16.24 亿元， 同比下降 0.60%；归母净利润 1.66 亿元，同比下降 28.37%；扣非归母净利润 1.35 亿元，同 比下降 11.11%。 |分析师及联系人 郑薇 SAC：S0590521070002 请务必阅读报告末页的重要声明 1 / 5 非金融公司|公司点评 glzqdatemark2 2024年08月26日 康恩贝(600572) 短期业绩承压，期待下半年恢复 | --- | --- | --- | |----------|--------------------------|------------------| | | | | | | 行 业： | 医药生物/中药Ⅱ | | | 投资 ...

证券代码：600572 证券简称：康恩贝 公告编号：临 2024-067 浙江康恩贝制药股份有限公司 关于公司 2024 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称：公司）根据上海证券交易所发布的 上市公司分行业信息披露指引《上市公司行业信息披露指引第六号——医药制造》 及《关于做好上市公司 2024 年半年度报告披露工作的通知》相关要求，现将公司 2024 年半年度主要经营数据披露如下： 一、报告期内分行业经营数据 | | | | | | 主营业务收入 | | 主营业务成本 | | | | | 毛利率（%） | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 行业 | 2024 年 | 2023 年 | 增长 | 2024 | 年 | 2023 年 | 增长 | 2024 | 2023 | 增长率 | | | | | | | | | 率 | 年 1- | 年 1 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 3.45 billion, a decrease of 8.40% compared to the same period last year[16]. - Net profit attributable to shareholders was CNY 382.20 million, down 25.95% year-on-year[16]. - The net profit after deducting non-recurring gains and losses was CNY 336.42 million, a decline of 19.02% compared to the previous year[16]. - The net cash flow from operating activities was CNY 305.22 million, a decrease of 30.48% year-on-year[16]. - Basic earnings per share were CNY 0.150, down 25.37% from CNY 0.201 in the same period last year[17]. - The weighted average return on net assets was 5.43%, a decrease of 1.78 percentage points compared to the previous year[17]. - The company reported a total profit of CNY 380,730,562.12 for the first half of 2024, down from CNY 842,450,864.95 in the same period of 2023[106]. - The net profit for the first half of 2024 is approximately CNY 380.73 million, a decrease of 55.1% compared to CNY 842.45 million in the same period of 2023[107]. Research and Development - The company increased its R&D expenses by approximately CNY 40 million during the reporting period[18]. - R&D expenses increased by approximately 43% to about 133 million yuan, with 15 authorized patents obtained during the reporting period[29]. - The company is focusing on innovation in drug development, particularly in traditional Chinese medicine, with ongoing projects like the oral liquid of Yang Chang Qing[34]. - The company is committed to enhancing its R&D capabilities by attracting high-quality talent and establishing an incentive mechanism for core R&D personnel[54]. - Research and development expenses for the first half of 2024 were CNY 17,544,030.98, a decrease of 17.5% compared to CNY 21,225,923.56 in the same period of 2023[106]. Market and Product Development - The company focuses on the pharmaceutical and health industry, primarily engaged in the R&D, manufacturing, and sales of traditional Chinese medicine and health products, with a strategic emphasis on a comprehensive range of traditional Chinese medicine products[20]. - The company is actively expanding its market presence and product offerings, particularly in the health supplement sector, with a focus on e-commerce platforms[22]. - The company has nearly 100 products with unique characteristics (exclusive varieties, formulations, and specifications), enhancing its competitive edge in the market[22]. - The company is leveraging the growing demand for health products driven by an aging population and increasing health awareness among consumers[21]. - The company is focusing on the development of new products and technologies, particularly in the field of traditional Chinese medicine, to capitalize on emerging market opportunities[21]. Environmental and Safety Management - The company is committed to safety and green development, with its plant-based pharmaceutical park awarded the national-level green factory title[31]. - The company has established a robust environmental management system and safety production management system to address increasing regulatory requirements and challenges[55]. - The company has implemented a comprehensive emergency response plan for environmental incidents, which has been filed with local authorities[75]. - The company’s environmental monitoring includes both manual and online monitoring, ensuring compliance with pollution discharge standards[66]. - The company has established a carbon emission reduction management group, implementing a management approach to ensure orderly execution of energy-saving and emission-reduction tasks[85]. Corporate Governance - The report has not been audited, and the management has ensured the accuracy and completeness of the financial report[3]. - The company completed the election of the 11th Board of Directors and Supervisory Board on August 16, 2024, to enhance governance efficiency[32]. - The company held its first extraordinary general meeting of 2024 on January 15, approving two resolutions related to board member appointments[56]. - The company has deepened mixed ownership reform to enhance governance and operational efficiency, including optimizing business authorization and management systems[26]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[76]. Shareholder and Equity Information - The company distributed a cash dividend of CNY 503.73 million, amounting to CNY 2.00 per 10 shares, based on a total share capital of 2,570,037,319 shares[94]. - The company’s major shareholder increased its stake by 2.27%, amounting to 274 million CNY, raising its ownership to 23.12%[26]. - The total number of ordinary shareholders reached 93,668 by the end of the reporting period[96]. - The largest shareholder, Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd., holds 587,278,040 shares, representing 22.85% of the total shares[96]. - The company has not reported any changes in its total share capital or structure during the reporting period[95]. Financial Position and Assets - Total assets at the end of the reporting period were CNY 10.25 billion, down 8.75% from the end of the previous year[16]. - The company's current assets totaled CNY 4,889,093,212.05, down from CNY 5,775,318,031.33, indicating a decrease of about 15.38%[98]. - The total liabilities decreased to CNY 3,293,236,855.68 from CNY 3,888,598,821.58, reflecting a reduction of approximately 15.29%[99]. - Cash and cash equivalents at the end of the period were 1,387,841,006.17 yuan, representing 13.53% of total assets, down 46.00% from the previous year[42]. - The total equity attributable to shareholders decreased to CNY 6,675,632,398.44 from CNY 7,041,063,708.95, a decline of about 5.19%[99]. Risk Management - There are no significant risks that materially affect the company's production and operations during the reporting period[10]. - The company has outlined various risks it may face in its operations, including industry policy changes, product quality risks, R&D innovation risks, raw material price fluctuations, and environmental and safety production risks[10]. - The company is actively monitoring industry policy changes, particularly regarding drug procurement and pricing, which could significantly impact the pharmaceutical sector[53]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[10]. - The company has not faced any violations of decision-making procedures regarding external guarantees[10]. Compliance and Reporting - The company has not disclosed any significant changes in its information disclosure practices during the reporting period[14]. - The company has not faced any non-standard audit opinions or bankruptcy restructuring matters during the reporting period[90]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[90]. - The company has not provided any guarantees for entities with a debt-to-asset ratio exceeding 70%[93]. - The company has not reported any significant related transactions that have not been reported in temporary announcements[91].

证券代码：600572 证券简称：康恩贝 公告编号：2024-066 浙江康恩贝制药股份有限公司 关于变更公司法定代表人并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称：公司）于 2024 年 8 月 16 日召开 2024 年第二次临时股东大会和职工代表大会，选举产生公司第十一届董事会、 监事会成员。同日，公司召开第十一届董事会第一次会议，选举姜毅先生为公司 第十一届董事会董事长，任期为三年，自董事会审议通过之日起至第十一届董事 会届满之日止。 因第十届董事会任期届满，自公司第十一届董事会产生之日起，公司原法定 代表人胡季强先生不再担任公司董事及董事长职务。根据《公司章程》第一章第 八条"董事长为公司的法定代表人"的规定，公司法定代表人应作相应变更，由 胡季强先生变更为姜毅先生。公司已向浙江省市场监督管理局申请变更公司《营 业执照》相关内容。 近日，公司完成法定代表人变更的工商登记手续，并于 2024 年 8 月 21 日取 得浙江省市场监督管理局换发的公司《营业执照 ...

北京观韬中茂（杭州）律师事务所 BEIJING GUANTAOLAW FIRM HANGZHOU OFFICE E-mail: guantato@guantao.com 邮编：310013 Tel: 86 571 8993 9691 Fax: 86 571 8993 9620 中国浙江省杭州市西湖区求是路 8 号公元大厦南楼 18 楼 http://www.guantao.com 18/F, South Bldg, Anno Domini Mansion, No. 8 Qiushi Road, Xihu District, Hangzhou, Zhejiang 310013, P. R. China 北京观韬中茂（杭州）律师事务所 关于浙江康恩贝制药股份有限公司 2024 年第二次临时股东大会的法律意见书 本法律意见书仅用于为公司本次股东大会见证之目的，不得用于其他任何目的或 用途。本所同意，公司将本法律意见书作为公司本次股东大会的公告材料，随其他需 公告的信息一起向公众披露，并依法对本所在其中发表的法律意见承担法律责任。 本所律师根据现行有效的中国法律、法规及中国证监会相关规章、规范性文件要 求，按照律师行 ...

（2024 年 8 月） 第一章 总则 董事会战略与投资决策委员会工作细则 浙江康恩贝制药股份有限公司 董事会战略与投资决策委员会工作细则 第一条 为适应公司战略发展需要，健全战略与投资决策程序，提高重大投资决 策的效益和决策的质量，完善风险控制体系和公司治理结构，根据《公司法》、《上 市公司治理准则》、《公司章程》及其他有关规定，公司特设立董事会战略与投资决 策委员会，并制定本工作细则。 第二条 董事会战略与投资决策委员会（以下简称"委员会"）是董事会按照《公 司章程》设立的专门工作机构，主要负责对公司中长期发展战略、重大投资决策进行 研究并提出建议或议案，对董事会负责。 第二章 人员组成 第三条 委员会成员由 3 至 5 名董事组成。 第四条 委员会委员由董事长、二分之一以上独立董事或者全体董事的三分之一 提名，并由董事会选举产生。 第五条 委员会设召集人一名，负责主持委员会工作；召集人由董事会过半数董 事确定。 第六条 委员会任期与董事会任期一致，委员任期届满，连选可以连任。期间如 有委员不再担任公司董事职务，自动失去委员资格，并根据上述第三至第五条规定补 足委员人数。 第七条 公司可以根据需要聘请内外 ...

经审查公司财务负责人、财务总监候选人谌明先生的职业、学历、职称、工作经 历、任职情况等有关资料,我们认为谌明先生具备与其行使职权相适应的任职资格和 能力，不存在《公司法》以及上海证券交易所《股票上市规则》、《上市公司自律监 管指引第１号一规范运作》规定的不得担任高级管理人员的情形，我们认为其具备担 任财务负责人、财务总监相关的专业知识、经验和能力，其任职资格符合《公司法》 等法律法规及规范性文件的相关规定。我们同意聘任谌明先生为公司财务负责人、财 务总监，并将该事项提交公司第十一届董事会第一次会议审议。 特此决议。 董事会审计委员会委员签字：『》「学ご》 （今19 浙江康恩贝制药股份有限公司 十一届董事会审计委员会 2024年第一次会议决议 浙江康恩贝制药股份有限公司（以下简称:公司)董事会审计委员会（以下简称: 审计委员会 ) 于 2024 年 8 月 16 日采用现场方式在杭州市滨江区滨康路 568 号康恩贝 中心 22 楼会议室召开了十一届董事会审计委员会 2024 年第一次会议,本次会议由审 计委员会召集人邱保印主持召开。审计委员会成员蒋倩、邱保印、牛宇龙均到会。会 议审议通过如下议案: 一、审议通过 ...